- Opus Materia
Low Risk of Hyperprogression with First-LineChemoimmunotherapy for Advanced Non-Small Cell Lung Canc
Low Risk of Hyperprogression with First-Line
Chemoimmunotherapy for Advanced Non-Small Cell
Lung Cancer: Pooled Analysis of 7 Clinical Trials

Lee X. Li, Federico Cappuzzo, Ignacio Matos, Mark A. Socinski,
Ashley M. Hopkins, Michael J. Sorich
Για να διαβάσετε το άρθρο ακολουθήστε το παρακάτω λινκ:
LOW RISK OF HYPERPROGRESSION WITH FIRST LINE CHEMOIMMUNOTHERAPY FOR ADVANCED NSCLC
.pdf
Download PDF • 492KB